First Trust/Confluence Small Cap Value Fund (FOVAX)

First Trust/Confluence Small Cap Value Fund (FOVAX) Financial Services Profile

First Trust/Confluence Small Cap Value Fund (FOVAX) operates as a closed-end management investment company, strategically focusing on U.S. small-capitalization equity securities. It aims to deliver both current income and capital appreciation by investing predominantly in value-oriented small-cap stocks, aligning with the market cap ranges of established small-cap indices.

What Is the Investment Thesis for FOVAX?

First Trust/Confluence Small Cap Value Fund (FOVAX) presents an investment vehicle focused on the U.S. small-capitalization value segment, a market known for its potential for long-term outperformance during specific economic cycles. The fund's commitment to allocating at least 80% of its assets to small-cap equities, defined by the Russell 2000 or S&P SmallCap 600 indices, provides clear exposure to this asset class. As a closed-end fund, its market price can trade at a discount or premium to its Net Asset Value (NAV), offering potential arbitrage opportunities for astute investors monitoring these fluctuations. The diversified approach to capturing value opportunities within the small-cap segment is a key value driver, aiming to identify undervalued companies with strong fundamentals. However, the fund's relatively small market capitalization of $10.80M ($10.80 million) introduces liquidity risks, particularly for larger institutional investors. Investors should monitor the fund's ability to consistently generate returns relative to its benchmark and the spread between its market price and NAV as critical performance indicators.

Based on FMP financials and quantitative analysis

FOVAX Key Highlights

• The fund maintains a strategic allocation of at least 80% of its total assets to equity securities of U.S. small-cap companies, aligning with Russell 2000 or S&P SmallCap 600 index market capitalization ranges.
• With a market capitalization of $10.80M, FOVAX is considered a relatively small fund, which may impact its liquidity profile for significant capital deployments.
• The fund's Beta of 1.03 indicates its price movements generally track the broader market with slightly higher volatility.
• As a closed-end fund, FOVAX's market price can deviate from its Net Asset Value (NAV), presenting potential for discounts or premiums.
• The fund does not currently pay a dividend, focusing its investment strategy on capital appreciation and income generation through its underlying portfolio holdings.

Who Are FOVAX's Competitors?

FOVAX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are FOVAX's Key Strengths?

• Dedicated focus on U.S. small-cap value equities, a segment with historical outperformance potential.
• Diversified portfolio approach designed to mitigate single-stock risk.
• Active management strategy aiming to identify undervalued assets and generate alpha.
• Clear investment mandate with at least 80% allocation to defined small-cap companies.

What Are FOVAX's Weaknesses?

• Relatively small market capitalization ($0.01B) may lead to liquidity risks for larger investors.
• Closed-end fund structure means market price can deviate significantly from Net Asset Value (NAV).
• Performance is highly dependent on the success of active management and market conditions favoring small-cap value.
• No dividend yield, which might deter income-focused investors.

What Could Drive FOVAX Stock Higher?

• Favorable market conditions for small-cap value stocks, driven by economic recovery and sector rotation, could enhance portfolio performance.
• Potential for a sustained period of small-cap outperformance relative to large-cap indices, attracting increased investor interest and capital inflows.
• Active management successfully identifying and investing in significantly undervalued small-cap companies that experience substantial price appreciation.
• Any narrowing of the discount to Net Asset Value (NAV) at which the fund's shares trade, potentially driven by improved market sentiment or fund-specific actions.

What Are the Key Risks for FOVAX?

• The fund's market price may trade at a significant discount to its Net Asset Value (NAV), leading to potential underperformance for shareholders even if the underlying portfolio performs well.
• The relatively small market capitalization of $10.80M could present liquidity risks, making it challenging for larger investors to enter or exit positions without impacting the share price.
• Underperformance of the fund's investment strategy relative to its small-cap value benchmarks, which could deter new investors and lead to existing shareholder dissatisfaction.
• General market downturns or specific adverse economic conditions that disproportionately affect small-capitalization companies, impacting the fund's underlying asset values.
• High competition within the asset management industry, particularly in the small-cap value segment, which could pressure fees or make alpha generation more challenging.

What Are the Growth Opportunities for FOVAX?

• **Increased Investor Appetite for Value Strategies:** In periods of market uncertainty or rising interest rates, investors often reallocate capital towards value-oriented strategies, which traditionally focus on companies with strong fundamentals trading below their intrinsic value. Should the broader market sentiment shift more decisively towards value investing, FOVAX, with its dedicated small-cap value mandate, could see increased demand for its shares. This trend could potentially lead to a reduction in any discount to NAV or even a premium, enhancing shareholder returns beyond just portfolio performance. The market for value funds remains substantial, with investors continuously seeking diversification and risk mitigation through such strategies.
• **Potential for Small-Cap Outperformance:** Small-capitalization stocks have historically demonstrated cycles of outperformance relative to large-cap equities, particularly during the early stages of economic recoveries or when inflation expectations rise. If the economic environment in 2026 and beyond favors smaller, more domestically focused companies, FOVAX's portfolio could benefit significantly from the appreciation of its underlying holdings. This cyclical advantage, driven by factors like innovation, M&A activity, and less analyst coverage, could translate into strong capital appreciation for the fund's shareholders, attracting new investors seeking exposure to this potential alpha source.
• **Diversification Benefits for Investor Portfolios:** Investing in small-cap value funds like FOVAX can offer significant diversification benefits for investors whose portfolios are heavily weighted towards large-cap growth stocks. Small-cap and value factors often exhibit low correlation with large-cap growth, providing a potential hedge during market rotations. As institutional investors increasingly seek to optimize portfolio construction and risk-adjusted returns, the role of specialized funds like FOVAX in providing targeted exposure to distinct market segments becomes more pronounced. This strategic diversification appeal could drive sustained interest and capital inflows into the fund over the long term.
• **Alpha Generation Through Active Management:** Despite the rise of passive investing, active management in less efficient market segments, such as small-cap value, still holds the potential for alpha generation. FOVAX's investment team actively screens for U.S. small-cap companies within the Russell 2000 and S&P SmallCap 600 indices that are deemed undervalued. Their expertise in fundamental analysis and stock selection aims to identify companies with strong balance sheets, sustainable business models, and attractive valuation multiples that may be overlooked by the broader market. Successful execution of this active strategy could lead to outperformance against its benchmarks, attracting investors seeking superior risk-adjusted returns.
• **Expansion of Assets Under Management (AUM):** While FOVAX currently has a relatively small market capitalization, sustained strong performance and increased investor interest could lead to an expansion of its Assets Under Management (AUM). A larger AUM base could provide several benefits, including improved liquidity for the fund's shares, potentially lower expense ratios through economies of scale, and enhanced market visibility. Growth in AUM would signify investor confidence in the fund's investment strategy and management capabilities, creating a positive feedback loop that could further attract capital and strengthen its market position within the competitive asset management industry.

What Opportunities Does FOVAX Have?

• Potential for small-cap stocks to outperform large-caps during specific economic cycles or recoveries.
• Increased investor interest in value strategies as a hedge against inflation or market volatility.
• Ability to capitalize on market inefficiencies within the less-covered small-cap segment.
• Growth in Assets Under Management (AUM) could improve liquidity and reduce expense ratios over time.

What Threats Does FOVAX Face?

• Sustained underperformance relative to its benchmark or peers could lead to investor outflows.
• General market downturns, particularly those impacting small-cap equities, could negatively affect portfolio value.
• Increased competition from other small-cap funds, both active and passive.
• Regulatory changes impacting investment funds or the financial services industry.

What Are FOVAX's Competitive Advantages?

• **Active Management Expertise:** The fund's ability to consistently identify undervalued small-cap companies through rigorous fundamental analysis provides a potential edge over passive strategies.
• **Specialized Focus:** Dedicated expertise and resources in the small-cap value segment allow for deeper market penetration and potentially better stock selection within this niche.
• **Diversified Portfolio Construction:** A diversified approach across various small-cap value stocks aims to reduce idiosyncratic risks and capture broader market opportunities.
• **Closed-End Fund Structure:** The fixed capital base of a closed-end fund can allow portfolio managers to take a longer-term view without the pressure of daily inflows/outflows, which can be an advantage in less liquid small-cap markets.

What Does FOVAX Do?

First Trust/Confluence Small Cap Value Fund (FOVAX) is structured as a closed-end management investment company, established with the objective of seeking current income and capital appreciation for its investors. The fund's core investment strategy mandates the allocation of at least 80% of its total assets, including any borrowed capital, to the equity securities of U.S.-based companies. These target companies are specifically defined as "Small-Cap Companies" at the time of investment, meaning their market capitalization falls within the size spectrum of firms included in either the Russell 2000 Index or the S&P SmallCap 600 Index, based on month-end data from the most recent 12-month period. This disciplined approach ensures a consistent focus on a specific segment of the equity market. As a closed-end fund, FOVAX issues a fixed number of shares that trade on an exchange, allowing its market price to fluctuate independently of its net asset value (NAV). This characteristic distinguishes it from open-end mutual funds, where shares are continuously issued and redeemed at NAV. The fund's emphasis on value stocks within the small-cap segment aims to capitalize on potentially undervalued companies that may offer significant growth prospects or attractive dividend yields over time. Its diversified portfolio approach is designed to mitigate risks associated with individual stock performance while seeking to capture broader value opportunities inherent in the small-capitalization market. Headquartered in Wheaton, US, FOVAX operates within the highly competitive asset management industry, catering to institutional and individual investors seeking exposure to actively managed small-cap value strategies.

What Products and Services Does FOVAX Offer?

• Invests primarily in equity securities of U.S.-based small-capitalization companies.
• Allocates at least 80% of its total assets to these small-cap equities, including borrowed capital.
• Defines 'Small-Cap Companies' by market value within the range of the Russell 2000 or S&P SmallCap 600 Index at the time of investment.
• Operates as a closed-end management investment company, meaning a fixed number of shares trade on an exchange.
• Seeks to achieve investment goals of current income and capital appreciation.
• Focuses on identifying and investing in value-oriented small-cap stocks.
• Manages a diversified portfolio to mitigate risks and capture broad market opportunities.

How Does FOVAX Make Money?

• Generates revenue through management fees charged on assets under management (AUM).
• Aims to attract and retain investors by delivering competitive returns from its small-cap value investment strategy.
• Benefits from the potential for its underlying portfolio holdings to appreciate in value and generate income.
• Manages a fixed pool of capital, with its market price determined by supply and demand on the exchange, separate from its NAV.

What Industry Does FOVAX Operate In?

The asset management industry, in which First Trust/Confluence Small Cap Value Fund (FOVAX) operates, is characterized by intense competition, evolving regulatory landscapes, and a continuous drive for differentiated investment strategies. The small-cap value segment, FOVAX's primary focus, represents a distinct niche within the broader equity market. Historically, small-cap stocks have demonstrated periods of significant outperformance relative to large-cap equities, particularly during economic recoveries or shifts in market leadership. However, they also carry higher volatility and liquidity risks. The competitive landscape includes numerous open-end mutual funds, exchange-traded funds (ETFs), and other closed-end funds offering small-cap or value-oriented strategies. FOVAX differentiates itself through its specific closed-end structure, which can lead to market price deviations from NAV, and its active management approach aimed at identifying undervalued opportunities within the Russell 2000 and S&P SmallCap 600 indices. The industry is currently experiencing trends such as the growth of passive investing, but active management in less efficient segments like small-cap value continues to attract investor interest seeking alpha.

Who Are FOVAX's Key Customers?

• Individual investors seeking exposure to actively managed small-cap value equities.
• Institutional investors, such as pension funds, endowments, and foundations, looking for diversification within their equity allocations.
• Financial advisors and wealth managers allocating client assets to specialized fund strategies.
• Investors interested in the potential for capital appreciation and income from the U.S. small-cap market segment.

First Trust/Confluence Small Cap Value Fund (FOVAX) Valuation Context

Relative to its peer group, FOVAX's quantitative score of 44/100 is below the peer average of 70/100.

FOVAX Financials

FOVAX Latest News

No recent news available for FOVAX.

FOVAX Analyst Consensus

FOVAX MoonshotScore

Common Questions About FOVAX (Financial Services)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources